Anti-tnfr2 antibodies and methods of use thereof
AssigneePfizer Inc.
InventorsTodd Douglas ASHWORTH, Yue LIU, Nicholas Andrew MARZE, Virginie MCMANUS
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies that bind to TNFR2 as well as uses of the antibodies and associated methods. The disclosure also provides processes for making, preparing, and producing antibodies that bind to TNFR2. Antibodies of the disclosure are useful in one or more of diagnosis, prophylaxis, or treatment of disorders or conditions mediated by, or associated with, TNFR2 activity.
Claims23
An isolated antibody that specifically binds to TNFR2, a heavy chain variable region (VH) and a light chain variable region (VL), comprising one or more selected from the group consisting of
- (i) comprising the CDR-H1, CDR-H2, and CDR-H3 sequences of a VH sequence selected from the group consisting of SEQ ID NO:
- 30, SEQ ID NO:
- 13, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 22, and SEQ ID NO:
- 29;
- and the CDR-L1, CDR-L2, and CDR-L3 sequences of a VL sequence selected from the group consisting of SEQ ID NO:
- 9, SEQ ID NO:
- 6, SEQ ID NO:
- 8, and SEQ ID NO:
- 4;
- (ii) a CDR-L1 sequence according to SEQ ID NO:
- 1;
- a CDR-L2 sequence according to SEQ ID NO:
- 7, and a CDR-L3 sequence according to SEQ ID NO:
- 3, and a CDR-H1 sequence according to SEQ ID NO:
- 10;
- a CDR-H2 sequence according to SEQ ID NO:
- 20;
- a CDR-H3 sequence according to SEQ ID NO:
- 12;
- and
- (iii) a CDR-L1 sequence according to SEQ ID NO:
- 1;
- a CDR-L2 sequence according to SEQ ID NO:
- 2, and a CDR-L3 sequence according to SEQ ID NO:
- 3, and a CDR-H1 sequence according to SEQ ID NO:
- 10;
- a CDR-H2 sequence according to SEQ ID NO:
- 11;
- a CDR-H3 sequence according to SEQ ID NO:
- 12.
An antibody comprising
- (i) one or both of a VH sequence encoded by the plasmid deposited at the ATCC and having ATCC Accession No. PTA-127528 and a VH sequence encoded by the plasmid deposited at the ATCC and having ATCC Accession No. PTA-127529;
- and a VL sequence encoded by the plasmid deposited at the ATCC and having ATCC Accession No. PTA-127531;
- or
- (ii) a HC sequence encoded by the plasmid deposited at the ATCC and having ATCC Accession No. PTA-127530 and a LC sequence encoded by the plasmid deposited at the ATCC and having ATCC Accession No. PTA-127532.
An isolated polynucleotide encoding one or more of
- (i) a HC and a LC, or both, of an antibody that binds to TNFR2, wherein said nucleic acid comprises one or more selected from the group consisting of the nucleic acid sequence of SEQ ID NO:
- 31, the nucleic acid sequence of SEQ ID NO:
- 32, the nucleic acid sequence of SEQ ID NO:
- 33;
- (ii) an isolated antibody that specifically binds to TNFR2, comprising a heavy chain (HC) sequence encoded by a nucleic acid sequence of SEQ ID NO:
- 33, and a light chain (LC) sequence encoded by a nucleic acid sequence of SEQ ID NO:
- 31;
- (iii) an isolated antibody comprising a HC sequence encoded by the plasmid deposited at the ATCC and having ATCC Accession No. PTA-127530 and a LC sequence encoded by the plasmid deposited at the ATCC and having ATCC Accession No. PTA-127532.
Dependencies are inferred from the claim text.